Skip to content

A study on the effect of the Individualised Homoeopathic Medicine in the treatment of Iron Deficiency Anaemia

A study on the effect of the Individualised Homoeopathic Medicine in comparison with Placebo in the treatment of Iron Deficiency Anaemia - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/086076
Enrollment
80
Registered
2025-04-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Individualised Homoeopathic Medicines: Individualised Homoeopathic Medicines in selective potency as in required repetition for 15 days. Control Intervention1: Placebo: One group will b

Sponsors

Dr Pruthviraj Rana
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Case pre-diagnosed or with clinical presentation of iron deficiency anemia. 2. Whose peripheral smear is +ve as microcytic hypochromic 3. All patients of both gender between 20-50 years of age.

Exclusion criteria

Exclusion criteria: 1. Anemia due to severe systemic disorders 2. Patients suffering from other severe systemic disease like Diabetes Mellitus, Hypertension, Thyroid disorders. 3. Whose HB level is below 8 mg/dL 4. Chronic other hemodynamic disorders like, Thalassemia etc. 5. Advanced and irreversible pathological cases which require immediate medical attention. 6. Patient taking other mode of treatment for Iron deficiency anaemia.

Design outcomes

Primary

MeasureTime frame
Betterment in Health of Patient.Timepoint: 3 Months.

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Partha Sarathi Mandal

Jawaharlal Nehru Homoeopathic Medical College

partha.mandal27317@paruluniversity.ac.in9375095471

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026